Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan adult leukaemia study group-AML 92 study

British Journal of Haematology

Volumn 120, Issue 1, 2003, Pages 56-62

  Miyazaki, Yasushi ^a   Kuriyama, Kazutaka ^a   Miyawaki, Shuichi ^b   Ohtake, Shigeki ^c   Sakamaki, Hisashi ^d   Matsuo, Tatsuki ^a   Emi, Nobuhiko ^e   Kobayashi, Tohru ^f   Matsushima, Takafumi ^g   Shinagawa, Katsuji ^h   Ohno, Ryuzo ⁱ   Tomonaga, Masao ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g GUNMA UNIVERSITY   (Japan)

^h OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

ⁱ AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

AML; Chemotherapy; Karyotype; Morphological dysplasia; Prognostic factor

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BIODIVERSITY; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CELL HETEROGENEITY; CHROMOSOME ANALYSIS; COMPARATIVE STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DYSPLASIA; GENETIC RISK; HIGH RISK POPULATION; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; MORPHOLOGY; PATIENT CODING; PHENOTYPE; PRIORITY JOURNAL; REMISSION; SURVIVAL RATE; TRILINEAGE DYSPLASIA;

ACUTE DISEASE; ADULT; CHI-SQUARE DISTRIBUTION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; DISEASE-FREE SURVIVAL; HUMANS; JAPAN; KARYOTYPING; LEUKEMIA, MYELOID; MIDDLE AGED; MULTIVARIATE ANALYSIS; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE;

EID: 0037217515     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.03981.x     Document Type: Article

References (26)

1. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1985a) Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Annals of Internal Medicine, 103, 460-462.
2. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1985b) Proposed revised criteria for the classification of acute myeloid leukemia. Annals of Internal Medicine, 103, 626-629.
3. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1991) Proposals for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). British Journal of Haematology, 78, 325-329.
4. Borrow, J., Shearman, A.M., Stanton, Jr, V.P. Becher, R. Collins, T. Williams, A.J. Dube, I. Katz, F. Kwong, Y.L. Morris, C. Ohyashiki, K. Toyama, K. Rowley, J. & Housman, D.E. (1996) The t(7;11) (p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nature Genetics, 12, 159-167.
5. Brito-Babapulle, F. Catovsky, D. & Galton, D.A.G. (1987) Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. British Journal of Haematology, 66, 445-450.
6. Brunning, R.D. Matutes, E. Harris, N.L. & Flandrin, G. (2001) Acute Myeloid Leukaemia with Multilineage Dysplasia. In: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (ed. by E.S. Jaffe, N.L. Harris, H. Stein & J.W. Vardiman), pp. 88-89. IARC Press, Lyon.
7. Dastugue, N. Payen, C. Lafage-Pochitaloff, M. Bernard, P. Leroux, D. Huguet-Rigal, F. Stoppa, A.M. Marit, G. Molina, L. Michallet, M. Maraninchi, D. Attal, M. & Reiffers, J. for the BGMT Group (1995) Prognostic significance of karyotype in de novo acute myeloid leukemia. Leukemia, 9, 1491-1498.
8. Estienne, M.H., Fenaux, P., Preudhomme, C., Lai, J.L., Zandecki, M., Lepelley, P. & Cosson, A. (1990) Prognostic value of dysmyelo-poietic features in de novo acute myeloid leukaemia: A report on 132 patients. Clinical Laboratory Haematology, 12, 57-65.
9. Ferrant, A., Labopin, M., Frassoni, F., Prentice, H.G., Cahn, J.Y., Blaise, D., Reiffers, J., Visani, G., Sanz, M.A., Boogaerts, M.A., Lowenberg, B. & Gorin, N.C. (1997) Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European group for blood and marrow transplantation study. Blood, 90, 2931-2938.
10. Friedman, A.D. (1999) Leukemogenesis by CBF oncoprotein. Leukemia, 13, 1932-1942.
11. Goasguen, J.E., Matsuo, T., Cox, C. & Bennett, J.M. (1992) Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: Major importance of dysgranulopoiesis for remission and survival. Leukemia, 6, 520-525.
12. Gorlich, D. & Mattaj, I.W. (1996) Nucleocytoplasmic transport. Science, 271, 1513-1518.
13. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Gold-stone, A. (1998) The importance of diagnostics cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood, 92, 2322-2333.
14. Heany, M. & Golde, D.W. (1999) Myelodysplasia. New England Journal of Medicine, 340, 1649-1660.
15. Kraemer, D., Wozniak, R.W., Blobel, G. & Radu, A. (1994) The human can protein, a putative oncogene product associated with myeloid leukemogenesis, is a nuclear pore complex protein that faces the cytoplasm. Proceedings of the National Academy of Sciences of the United States of America, 91, 1519-1523.
16. Kuriyama, K., Tomonaga, M., Matsuo, T., Kobayashi, T., Miwa, H., Shirakawa, S., Tanimoto, M., Adachi, K., Emi, N., Hiraoka, A., Tominaga, N., Imai, K., Asou, N., Tsubaki, K., Takahash, I., Minami, S., Yoshida, M., Murakami, H., Minato, K., Oshima, T., Furusawa, S., Ohno, R. & Japan Adult Leukemia Study Group (JALSG) (1994) Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage myelodysplasia. British Journal of Haematology, 86, 767-773.
17. Kuriyama, K., Miyazaki, Y., Arimura, K., Nagai, K., Nakamura, H., Matsuo, T. & Tomonaga, M. (1995) Morphological comparison of dysplastic changes between de novo acute myeloid leukemia (AML) with trilineage myelodysplasia and AML developed from de novo yelodysplastic syndromes. Leukemia Research, 19, 121-125.
18. Kuriyama, K., Tomonaga, M., Kobayashi, T., Takeuchi, J., Ohshima, T., Furusawa, S., Saitoh, K. & Ohno, R. (2001) Morphological diagnoses of the Japan Adult Leukemia Study Group acute myeloid leukemia protocols: Central review. International Journal of Hematology, 73, 93-99.
19. von Lindern, M., Fornerod, M., van Baal, S., Jaegle, M., de Wit, T., Buijs, A. & Grosveld, G. (1992) The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Molecular and Cellular Biology, 12, 1687-1697.
20. Lowenberg, B., Downing, J. & Burnett, A. (1999) Acute myeloid leukemia. New England Journal of Medicine, 341, 1051-1062.
21. Miyawaki, S., Tanimoto, M., Kobayashi, T., Minami, S., Tamura, J., Omoto, E., Kuriyama, K., Hatake, K., Saito, K., Kanamaru, A., Oh, H., Ohtake, S., Asou, N., Sakamaki, H., Yamada, O., Jinnai, I., Tsubaki, K., Takeyama, K., Hiraoka, A., Matsuda, S., Takahashi, M., Shimazaki, C., Adachi, K., Kageyama, S. & Ohno, R. for the Japan Adult Leukemia Study Group (JALSG) (1999) No beneficial effect from addition of etoposide to daunorubicin cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: The JALSG-AML92 study. International Journal of Hematology, 70, 97-107.
22. Morel, P., Hebbar, M., Lai, J.L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F. & Fenaux, P. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia, 7, 1315-1323.
23. Nakamura, T., Largaespada, D.A., Lee, M.P., Johnson, L.A., Ohyashiki, K., Toyama, K., Chen, S.J., Willman, C.L., Chen, I.M., Feinberg, A.P., Jenkins, N.A., Copeland, N.G. & Shaughnessy, Jr, J.D. (1996) Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukemia. Nature Genetics, 12, 154-158.
24. Pandolfi, P.P. (2001) Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Human Molecular Genetics, 10, 769-775.
25. Toyama, K., Ohyashiki, K., Yoshida, Y., Abe, T., Asano, S., Hirai, H., Hirashima, K., Hotta, T., Kuramoto, A., Kuriya, S., Miyazaki, T., Kakishita, E., Mizoguchi, H., Okada, M., Shirakawa, S., Takaku, F., Tomonaga, M., Uchino, H., Yasunaga, K. & Nomura, T. (1993) Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndrome: A multicentric study in Japan. Leukemia, 7, 499-508.
26. Wheatley, K., Burnett, A.K., Goldstone, A.H., Gray, R.G., Hann, I.M., Harrison, C.J., Rees, J.K., Stevens, R.F. & Walker, H. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. British Journal of Haematology, 107, 69-79.